This content is PDF only. Please click on the PDF icon to access.
In 1958 cyclophosphamide was introduced as one of a series of alkylating agents for the treatment of cancer. It has proved to be an effective agent in the therapy of chronic lymphatic leukemia, Hodgkin's disease and lymphoma, multiple myeloma, and a few solid tumors including breast and ovarian cancers. Though it produces alopecia and hemorrhagic cystitis and is expensive, it has the advantages of causing less platelet depression than other alkylating agents and of oral or intravenous administration; and proper dosage ranges can be easily established for the drug.
A symposium was held in London in October, 1963, to discuss
Cyclophosphamide (Cytoxan). Proceedings of a Symposium (London), October 1963.. Ann Intern Med. 1965;63:927–928. doi: 10.7326/0003-4819-63-5-927_2
Download citation file:
Published: Ann Intern Med. 1965;63(5):927-928.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use